Results 221 to 230 of about 76,403 (315)

Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma

British Journal of Haematology, EarlyView.
Translational analyses from the KarMMa trial (NCT03361748) highlight that baseline tumour burden, immune environment and chimeric antigen receptor (CAR) T‐cell dynamics influence both the initiation and durability of response to idecabtagene vicleucel (ide‐cel) in relapsed and refractory multiple myeloma.
Nathan Martin, Ethan Thompson, Nicholas Stong, Yang Xu, Olivia Finney, Julie Rytlewski, Erin Flynt, Jessica Marfo, Dante B. Descalzi‐Montoya, Irene Manrique, Bruno Paiva, Nikhil Munshi, Timothy B. Campbell, Shari M. Kaiser   +13 more
wiley   +1 more source

Development of an In-House Antigen ELISA Using Monoclonal and Polyclonal Antibodies Against an Isolated Canine Distemper Virus. [PDF]

Vet Med Sci
Kökkaya S, Göksu AG.
europepmc   +1 more source

Mass Spectrometry-Based Proteomics in Clinical Diagnosis of Amyloidosis and Multiple Myeloma: A Review (2012-2024). [PDF]

J Mass Spectrom
Kratka K, Sistik P, Olivkova I, Kusnierova P, Svagera Z, Stejskal D.   +5 more
europepmc   +1 more source

The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

British Journal of Haematology, EarlyView.
In oncological patients SIR measures like the mGPS have great impact on prognosis at starting therapy. We recorded at admission for allo‐HCT the mGPS in 2201 patients: score 0 CRP/sALB normal; score 1 CRP >10mg/dl; score 2 CRP >10mg/dl + sALB <35g/L. Multivariate analysis revealed a significant impact with a low GPS score for OS: mGPS 1 vs.
Hartmut Bertz, Jörg Sahlmann, Donald C. McMillan, Claudia Wehr, Jesus Duque‐Afonso, Kristina Maas‐Bauer, Ralph Wäsch, Julia Nikolaychuk, Christine Greil, Jann Arends, Jürgen Finke, Robert Zeiser   +11 more
wiley   +1 more source

Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders. [PDF]

Hematol Rep
Hanbali A, Alamer A, Alhayli S.
europepmc   +1 more source

Peroxidation of proteins and lipids in suspensions of liposomes, in blood serum, and in mouse myeloma cells.

, 2000
Janusz M. Gebicki, Juan Du, Jennifer J.P. Collins, Helen J. Tweeddale   +3 more
openalex   +2 more sources

The Role of Histone Methyltransferase SETDB1 in Normal and Malignant Hematopoiesis

Cancer Science, EarlyView.
In this review, we discuss the role of SETDB1 in gene regulation, including an overview of its structural features and key cofactors. We also highlight the lineage‐specific roles of SETDB1 in both normal hematopoietic processes and hematological malignancies, emphasizing its function as an immune checkpoint molecule that suppresses natural killer cell ...
Yu‐Hsuan Chang, Susumu Goyama
wiley   +1 more source

Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial. [PDF]

Pharmaceutics
Kacin E, Sewduth RN.
europepmc   +1 more source

Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR‐T Cells Against B‐Cell Lymphoma

Cancer Science, EarlyView.
In the tumor microenvironment, selinexor suppresses tumor cell growth and prevents macrophages from polarizing to M2 populations. The lower concentration of selinexor decreases CAR‐T cell exhaustion, enhances its cytotoxicity, and upregulates NGFR expression to prompt CAR‐T cell proliferation.
Wenjing Luo, Jia Xu, Chenggong Li, Lu Tang, Yingying Li, Xindi Wang, Zhuolin Wu, Yinqiang Zhang, Heng Mei, Yu Hu   +9 more
wiley   +1 more source